Table 1 Characteristics of patients participating in the study: CQ–PQ combined treatment in 14 days (T14) and intermittent single doses (ISD)

Total patients

67

86

By Gender (n)

Female

Male

Female

Male

0.274 ^a

Age range in years

 1–5

2

3

2

3

Age by gender (male/age, 0.58; female/age, 0.413)

 6–15

13

6

6

13

 16–25

6

6

9

9

 26–40

4

6

9

12

 >40

9

12

10

13

Total

34

33

36

50

Body weight: median (IQR), range

50 (25), 9.6–108

57 (20), 14–104

0.219 ^b

Days of symptoms: median (IQR), range

5 (4), 1–20

4 (4), 1–30

0.265 ^b

Axial temperature (°C): median (IQR), range

37.45 (1.1), 36–40

37.5 (1), 36.5–40.1

0.183 ^b

Asexual parasitaemia/µl: median (IQR), range

4888 (5379), 512–28,940

3830 (5443), 490–28,424

0.20 ^b

Samples with gametocytes

100 %

100 %

0.073 ^b

Gametocytaemia/µl: median (IQR), range

697 (959), 45–5684

999 (1305), 35-12,102

Clinical symptoms indicated by patients as having occurred within 2 days of arrival to our diagnosis facility (% of patients indicating each condition)

0.265 ^c

 Fever

98.1

100

 Headache

98.1

96.5

 Mialgias

89.5

89.5

 Arthralgias

80.6

83.7

 Paroxysm

77.6

68.6

 Jaundice

11.9

12.8

 Blisters

2.9

3.4

 Pruritus

0

0